Skip to Main Content

Paper Details

Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy.
Nature
48
2022
Androgen, Androgen receptor, BRAF, MEK, androgen, androgen receptor, cancers, melanoma, metastatic melanoma, mice, patients, testosterone, tumour, tumours
Author NameAffiliation
Joseph R DanieleThe University of Texas MD Anderson Cancer Center
Alexander J LazarThe University of Texas MD Anderson Cancer Center
Alexander J LazarThe University of Texas MD Anderson Cancer Center
Alexander J LazarThe University of Texas MD Anderson Cancer Center
Michael A DaviesThe University of Texas MD Anderson Cancer Center
Michael A DaviesThe University of Texas MD Anderson Cancer Center
Jeffrey J KovacsThe University of Texas MD Anderson Cancer Center
Jeffrey E GershenwaldThe University of Texas MD Anderson Cancer Center
Jeffrey E GershenwaldThe University of Texas MD Anderson Cancer Center
Georgina V LongMelanoma Institute Australia, The University of Sydney, and Royal North Shore and Mater Hospitals
Phillip A FutrealThe University of Texas MD Anderson Cancer Center
Hussein A TawbiThe University of Texas MD Anderson Cancer Center
Linghua WangThe University of Texas MD Anderson Cancer Center
Timothy P HeffernanThe University of Texas MD Anderson Cancer Center
Jennifer A WargoThe University of Texas MD Anderson Cancer Center
Jennifer A WargoThe University of Texas MD Anderson Cancer Center
  • 1 - 16

Datasets

Release 1.2